Interactive Decision Support Tool: Expert Management Recommendations for Patients With β-Thalassemia
  • CME

image_fe88fb7737ca48a79caf30603d63e3dd.png
LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with β-thalassemia with those of 4 renowned thalassemia experts.

Jeanne Boudreaux, MD
person default
Stephanie A. Fritch Lilla, MD
Janet L. Kwiatkowski, MD, MSCE
Sujit Sheth, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: April 22, 2021 Expiration: April 21, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Provide optimal care for patients with β-thalassemia, considering the available clinical evidence as well as expert and guideline recommendations

  • Plan therapeutic approaches to reducing transfusion dependence through use of erythroid maturation agent

  • Evaluate emerging gene therapy strategies and their potential role in management of patients with β-thalassemia

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Jeanne Boudreaux, MD

Associate Professor of Pediatrics
Director of the Comprehensive Thalassemia Program
Clinical Director of Hematology

Aflac Cancer & Blood Disorders Center
Children's Healthcare of Atlanta
Emory University
Atlanta, Georgia

Jeanne Boudreaux, MD, has disclosed that she has received consulting fees from Bluebird Bio, Chiesi, and Celgene.
Stephanie A. Fritch Lilla, MD

Pediatric Hematologist Oncologist
Director, 
Thalassemia Program
Department of Pediatric Hematology/Oncology
Children's Minnesota
Minneapolis, Minnesota

Stephanie A. Fritch Lilla, MD, has no relevant financial relationships to disclose.
Janet L. Kwiatkowski, MD, MSCE

Professor of Pediatrics
Perelman School of Medicine of the University of Pennsylvania
Director, Thalassemia Program
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Janet L. Kwiatkowski, MD, MSCE, has disclosed that received consulting fees from Agios, Bluebird Bio, Celgene (now Bristol-Myers Squibb), Imara, and Silence Therapeutics; and has received funds for research support from ApoPharma, Bluebird Bio, Novartis, Sangamo, and Terumo BCT
Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Sujit Sheth, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb/Celgene, DisperSol/DST, and La Jolla and consulting fees from Agios, Bluebird Bio, Bristol-Myers Squibb/Celgene, Chiesi, and CRISPR/Vertex.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael Andrie, PhD has no relevant conflicts of interest to disclose.
Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no relevant conflicts of interest to disclose.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD has no relevant conflicts of interest to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with β-thalassemia.

Goal

The goal of this activity is to improve the competence of learners to apply the latest practice-changing data in the individualized clinical management of patients with β-thalassemia.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 22, 2021, through April 21, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.

You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Disclaimer

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Management Recommendations for Patients With β-Thalassemia” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with β-thalassemia. The information provided is based on clinical guidelines for the management of patients with β-thalassemia and expert recommendations of Jeanne Boudreaux, MD; Stephanie A. Fritch Lilla, MD; Janet L. Kwiatkowski, MD, MSCE; and Sujit Sheth, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: Expert Management Recommendations for Patients With β-Thalassemia” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2021 Clinical Care Options, LLC. All rights reserved.

Related Content

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Downloadable slideset with highlights from key blood cancers and nonmalignant blood disorders as presented at EHA Virtual Congress 2021, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 16, 2021

Dr. Corey S. Cutler shares his views on current and future graft-vs-host disease (GVHD) therapies in this commentary from Clinical Care Options (CCO)

Corey S. Cutler, MD, MPH, FRCPC Released: April 27, 2021

On-demand Webcast updated with data from ASH 2020 with expert faculty discussing recent data on management of hemophilia A, presented by Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Michael Callaghan, MD person default Rebecca Kruse-Jarres, MD, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: February 25, 2021 Expired: February 24, 2022
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Celgene Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue